4.6 Article

Topical methyl-aminolevulinate photodynamic therapy using red light-emitting diode light for treatment of multiple actinic keratoses: A randomized, double-blind, placebo-controlled study

期刊

出版社

MOSBY-ELSEVIER
DOI: 10.1016/j.jaad.2008.05.031

关键词

-

资金

  1. PhotoCure ASA, Oslo, Norway
  2. Galderma
  3. DUSA
  4. DOW
  5. Genentech
  6. Connetics
  7. Allergan
  8. Hill
  9. Centocor
  10. Stiefel
  11. Novartis
  12. Medicis
  13. Altana
  14. Astellas
  15. 3M
  16. Obagi
  17. Isolagen
  18. Contura
  19. Anacor

向作者/读者索取更多资源

Background: The use of light-emitting diode light offers practical advantages in photodynamic therapy (PDT) with topical methyl-aminolevulinate (MAL) for management of actinic keratoses (AK). Objective: We Sought to evaluate the efficacy of MAL PDT using red light-emitting diode light. Methods: We conducted a multicenter, double-blind, randomized study. A total of 49 patients with 363 AK lesions had 16.8% MAL cream applied under occlusion for 3 hours, and 47 patients with 360 AK lesions had vehicle cream similarly applied. The lesions were then illuminated (630 nm, light dose 37 J/cm(2)) with repeated treatment 1. week later. Complete lesion and patient (all lesions showing complete response) response rates were evaluated 3 months after last treatment. Results: MAL PDT was Superior (P < .0001) to vehicle PDT with respect to lesion complete response (86.2% vs 52.2%, odds ratio 6.9 [95% confidence interval 4.7-10.3]) and patient complete response (59.2% vs 14.9%, odds ratio 13.2 [95% confidence interval 4.1-43-1]). Limitations: The study population may not be representative of all patients with AK. Conclusion: MAL PDT using red light-emitting diode light is an appropriate treatment alternative for multiple AK lesions.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据